Loading
DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.87, animal model 0.70, genetic association 0.62, somatic mutation 0.63). IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Prostate Adenocarcinoma.
In plain words · DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding.
No product in this corpus aims at DCC yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA DCC: RNA tissue enhanced (brain 3 nTPM, testis 7 nTPM); high antibody staining in 1 normal tissue. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma, Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P43146; CIViC gene DCC; IntOGen DCC; Human Protein Atlas DCC tissue; Open Targets ENSG00000187323 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Fearon E.R. et al, Science, 1990, "Identification of a chromosome 18q gene that is altered in colorectal cancers". Source.
Sources: HGNC HGNC:2701 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43146 (protein name, function text, keywords and locations (REST API)); CIViC gene DCC (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0)); Open Targets ENSG00000187323 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: colorectal cancer 0.51 (GraphQL API, CC0)); IntOGen DCC (driver in 5 cohorts (Act 2, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumour suppressor gene. Location: Membrane (UniProt). Locus 18q21.2 (HGNC).
RNA: tissue enhanced (brain 3 nTPM, testis 7 nTPM), detected in some normal tissues.
Medium: Cerebral cortex, Stomach.
RNA cancer enhanced: Glioblastoma Multiforme 2 pTPM, Lung Squamous Cell Carcinoma 1 pTPM.
No cancer stained high; medium in glioma, ovarian cancer, pancreatic cancer, skin cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DCC" OR ABSTRACT:"DCC" OR TITLE:"DCC netrin 1 receptor" OR ABSTRACT:"DCC netrin 1 receptor" OR TITLE:"Netrin receptor DCC" OR ABSTRACT:"Netrin receptor DCC" OR TITLE:"IGDCC1" OR ABSTRACT:"IGDCC1" OR TITLE:"NTN1R1" OR ABSTRACT:"NTN1R1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DCC, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.